tldrdailynews.com logo

"Amgen's Wegovy: Promising Early Data for Taperable Weight-Loss Drug"

1 min read
Source: STAT
"Amgen's Wegovy: Promising Early Data for Taperable Weight-Loss Drug"
Photo: STAT
TL;DR

Amgen is testing a unique strategy with its obesity drug candidate, MariTide, to see if it can be tapered down to lower or less frequent doses over time, potentially providing longer-lasting weight loss than existing popular obesity drugs like Wegovy and Zepbound. The ongoing Phase 2 trial aims to titrate participants up on MariTide and then transition them to a less intensive dosing regimen to assess the drug's effectiveness, challenging the current expectation of lifelong consistent dosing for obesity drugs.

Topics:businesshealth#amgen#dosing-regimen#health#maritide#obesity-drug#weight-loss
Share this article
  1. Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down  STAT
  2. Amgen's Weight-Loss Drug Shows Lasting Results in Early Study  Bloomberg
  3. Promising early data details on Amgen weight-loss drug published  SaltWire NS
  4. Amgen rises on promising early data for weight-loss drug  XM

Want the full story? Read the original reporting

Read on STAT